Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab

J Clin Oncol. 2011 Apr 10;29(11):e308-11. doi: 10.1200/JCO.2010.32.6082. Epub 2011 Jan 24.

Authors

Slim Fellah¹, Nadine Girard, Olivier Chinot, Patrick J Cozzone, Virginie Callot

Affiliation

¹ Centre de Résonance Magnétique Biologique et Médicale, Unité Mixte de Recherche 6612 Centre National de Recherche Scientifique, Faculté de Médecine de Marseille, Université de Méditerranée (Aix-Marseille II), Marseille, France.

PMID: 21263101
DOI: 10.1200/JCO.2010.32.6082

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bevacizumab
Brain Neoplasms / drug therapy*
Brain Neoplasms / pathology
Camptothecin / administration & dosage
Camptothecin / analogs & derivatives
Fatal Outcome
Glioblastoma / drug therapy*
Glioblastoma / pathology
Humans
Irinotecan
Magnetic Resonance Angiography*
Male
Neoplasm Recurrence, Local / drug therapy*
Neoplasm Recurrence, Local / pathology
Spin Labels

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Spin Labels
Bevacizumab
Irinotecan
Camptothecin